Arthritis Patents (Class 514/825)
-
Patent number: 6787518Abstract: Drugs for preventing or treating diseases that involve the destruction and degeneration of articular cartilage tissue contain a parathyroid hormone related peptide (PTHrP) or a PTHrP derived substance as an effective ingredient.Type: GrantFiled: August 19, 1997Date of Patent: September 7, 2004Inventors: Yukio Kato, Masahiro Iwamoto, Tatsuya Koike
-
Patent number: 6774131Abstract: A pharmaceutical composition for therapeutically treating prostate cancer, the pharmaceutical composition containing N-[6-methoxy-5-(2-methoxyphenoxy)-2-(2-pyrimidinyl)-4-pyri midinyl]-2-phenylethenesulfoneamide or a pharmaceutically acceptable salt thereof as the effective component.Type: GrantFiled: July 19, 2002Date of Patent: August 10, 2004Assignee: Yamanouchi Pharmaceutical Co., Ltd.Inventors: Hironori Yuyama, Akira Fujimori, Masanao Sanagi, Hironori Harada, Akiko Koakutsu, Mikiko Mori, Nobuyuki Yamamoto
-
Patent number: 6767564Abstract: The present invention provides a non-toxic therapy and a novel use for Bowman Birk Inhibitor (BBI), as administered in Bowman Birk Inhibitor Concentrate (BBIC), for the treatment of autoimmune diseases in a patient, wherein the disease is characterized by chronic inflammation, such as rheumatoid arthritis; and more particularly for the treatment of those diseases that are characterized by chronic neuroinflammation and/or demyelination, such as Multiple Sclerosis (MS) and Guillain Barre Syndrome (GBS). In addition, the present invention provides methods for using BBI/BBIC to reduce, inhibit, suppress or prevent the chronic inflammation in such patients; and more particularly, to reduce, inhibit, suppress or prevent the chronic neuroinflammation and demyelination that occurs when the patient's nerve tissue is affected by the disease.Type: GrantFiled: August 31, 2001Date of Patent: July 27, 2004Assignee: The Trustees of the University of PennsylvaniaInventors: Abdolmohamad Rostami, Ann R. Kennedy
-
Patent number: 6756396Abstract: New compounds useful in photodynamic therapy are of the formula and their 1,4-diene isomers and the metallated and/or labeled and/or conjugated forms thereof wherein each R1 is independently alkyl (1-6C); each n is independently an integer of 0-6; and R2 is vinyl or a derivative form thereof.Type: GrantFiled: June 6, 2000Date of Patent: June 29, 2004Assignees: QLT Inc., The University of British ColumbiaInventors: Ethan Sternberg, David Dolphin, Julia G. Levy, Anna M. Richter, David W. C. Hunt, Ashok Jain, Elizabeth M. Waterfield, Ronald E. Boch
-
Patent number: 6733794Abstract: A composition for topical analgesic and antiseptic use which consists essentially of a approximately equal proportions of alcohol, turpentine, and eucalyptus oil.Type: GrantFiled: December 17, 1999Date of Patent: May 11, 2004Inventors: Edward L. Ingram, Mary Scott
-
Patent number: 6723345Abstract: Topical gelled compositions comprising an optional drug dispersed within a polymer matrix, methods of producing the same and treatments with the complex.Type: GrantFiled: November 7, 2001Date of Patent: April 20, 2004Assignee: L.A.M. Pharmaceutical Corp.Inventors: Alan Drizen, Peter Rothbart, Gary M. Nath
-
Patent number: 6720012Abstract: An analgesic composition that can be applied topically comprises boric acid and a suitable carrier. The inventive analgesic composition can be used to provide pain relief to a person suffering from arthritis and any general pain associated with muscles or joints.Type: GrantFiled: April 1, 2002Date of Patent: April 13, 2004Assignee: A & L of Michigan, Inc.Inventor: Annie L. Jones
-
Patent number: 6713096Abstract: The invention provides compositions such as dietary supplements. Such compositions can be used to reduce pain, inflammation, stiffness, and/or discomfort associated with inflammatory conditions such as arthritis. The invention also provides methods for reducing pain, inflammation, stiffness, and/or discomfort associated with inflammatory conditions such as arthritis.Type: GrantFiled: January 4, 2002Date of Patent: March 30, 2004Assignee: Melaleuca, Inc.Inventor: Suk H. Cho
-
Patent number: 6703049Abstract: The present invention relates to a novel angiogenesis inhibitor, more particularly, arsenolite (solid As4O6) and composition containing the same. The arsenolite of the present invention inhibits endothelial cell proliferation and tube formation so that it can be used for medication of various angiogenic diseases.Type: GrantFiled: April 4, 2001Date of Patent: March 9, 2004Inventors: II Ju Bae, Kang Moon Seo, Chang Hun Rhee
-
Patent number: 6680304Abstract: The invention relates to novel disaccharides of formula (I), wherein R1 is selected from the group consisting of hydrogen, linear or branched (C1-C4) alkyl, phenylalkyl with less than ten carbon atoms and —COCH3; R2 is selected from the group consisting of hydrogen, —COCH3 and SO3M; R3 is selected from the group consisting of hydrogen, linear or branched (C1-C4) alkyl, phenylalkyl with less than ten carbon atoms, —COCH3 and y —COPh, Ph being phenyl; G is selected from amongst —COOR4 and —COOM, R4 is selected from the group consisting of hydrogen, (C1-C2)-alkyl and arylalkyl with less than sixteen carbon atom; A is selected from the group consisting of hydrogen, —SO3H, —SO3M and —COCH3; B is selected from the group consisting of hydrogen, —SO3H, —SO3M and —COCH3, wherein either A or B are necessarily either —SO3H or —SO3M, M being a an organic or metallic cation.Type: GrantFiled: January 10, 2003Date of Patent: January 20, 2004Assignee: Bioiberica, S.A.Inventors: Francisco Javier Vila Pahi, Francesc Flores Salgado, Ramon Ruhi Roura, Narcís Arnau Pastor
-
Patent number: 6669623Abstract: A medical preparation for treating arthrosis, arthritis and other rheumatic joint diseases comprises a suspension consisting of one-shelled or multi-shelled nanoscalar particles composed of a core containing iron oxide and of an inner shell with groups capable of forming cationic groups or, optionally, of at least one outer shell with neutral and/or anionic groups. Radionuclides and substances, said substances being cytotoxically active when subjected to heat, are bound to the inner shell. The preparation that is injected into the joint cavity and subjected to an alternating electromagnetic field promises an excellent treatment outcome due to the high rate of phagocytosis and the trimodal combinatorial effect of thermotherapy, radiotherapy and chemotherapy.Type: GrantFiled: January 23, 2002Date of Patent: December 30, 2003Assignee: MagForce Applications GmbHInventor: Andreas Jordan
-
Patent number: 6669941Abstract: This invention relates to compositions and methods comprising “lymphotoxin-&bgr; receptor blocking agents”, which block lymphotoxin-&bgr; receptor signalling. Lymphotoxin-&bgr; receptor blocking agents are useful for treating lymphocyte-mediated immunological diseases, and more particularly, for inhibiting Th1 cell-mediated immune responses. This invention relates to soluble forms of the lymphotoxin-&bgr; receptor extracellular domain that act as lymphotoxin-&bgr; receptor blocking agents. This invention also relates to the use of antibodies directed against either the lymphotoxin-&bgr; receptor or its ligand, surface lymphotoxin, that act as lymphotoxin-&bgr; receptor blocking agents. A novel screening method for selecting soluble receptors, antibodies and other agents that block LT-&bgr; receptor signalling is provided.Type: GrantFiled: April 30, 1999Date of Patent: December 30, 2003Assignee: Biogen, Inc.Inventors: Jeffrey L. Browning, Christopher D. Benjamin, Paula S. Hochman
-
Patent number: 6670347Abstract: This invention relates to new 19-nor-17&agr;-pregna-1,3,5(10)-trien-17&bgr;-ols with a 21,16&agr;-lactone ring of formula II, process for their production and pharmaceutical preparations that contain these compounds as well as 17&agr;-cyanomethylated estra-1,3,5(10)-trienes, which produce intermediate products on the way to the 19-nor-17&agr;-pregna-1,3,5(10)-trien-17&bgr;-ols. The 19-nor-17&agr;-pregna-1,3,5(10)-trien-17&bgr;-ols produce novel selective estrogens, which contrast to standard estrogens, such as estradiol, show a preference for one of the two known estrogen receptors, estrogen receptor alpha.Type: GrantFiled: September 27, 2001Date of Patent: December 30, 2003Assignee: Schering AGInventors: Gerd Müller, Uwe Kollenkirchen, Dirk Kosemund, Karl-Heinrich Fritzemeier, Walter Elger
-
Patent number: 6664406Abstract: The present invention relates to a nervonic acid derivatives of formula (I) CH3—(CH2)7—CH═CH—(CH2)13—C(O)—O—(CH2)3—OR (I) wherein R is hydrogen (H) or a residue of a carboxylic acid; or a salt of the compound where R is H; or a bioprecursor, prodrug thereof. Those compounds wherein R is other than H have pharmacological activity, in particular anti-inflammatory and immunomodulatory effects. Those compounds wherein R is H can be used to prepare the pharmacologically active derivatives.Type: GrantFiled: August 19, 2002Date of Patent: December 16, 2003Assignee: Croda International PLCInventors: Keith Coupland, Yann Raoul
-
Patent number: 6656925Abstract: This invention relates to the compositions and method of treating and preventing arthritis, repairing of articular joint surfaces and the relief of symptoms associated with arthritis. The composition comprises bio-affecting agents to reduce nitric oxide production and increase chondroprotective agents. The preferred composition comprises; nitric oxide synthase inhibitors, nitric oxide scavangers, and amino sugars. Nitric oxide synthase inhibitors and nitric oxide scavengers reduce the level of nitric oxide, the free radical responsible for the degradation of articular cartilage. Amino sugars are the building blocks of articular cartilage and have anti-inflammatory actions.Type: GrantFiled: February 5, 2002Date of Patent: December 2, 2003Assignee: Advanced Medical InstrumentsInventor: Edward J. Petrus
-
Patent number: 6653352Abstract: A composition containing capsicium extract together with other ingredients to neutralize the discomfort resulting from the application of capsicium extract to the skin enabling treatment of many types of discomforts, including arthritis pain, neuropathy, post surgical scarring, hemorrhoid pain and itching, and pruritis without the discomfort normally associated with the topical application of capsicium extract.Type: GrantFiled: March 6, 2001Date of Patent: November 25, 2003Assignee: Medical Merchandising, Inc.Inventors: Teresa Leigh Barr, Stephen D. Holt
-
Patent number: 6645482Abstract: Compositions with synergistic anti-inflammatory effects in inflammatory diseases resulting from activation and consequent degranulation of mast cells and followed by secretion of inflammatory biomolecules from the activated mast cells, composed of a heavily sulfated, non-bovine proteoglycan such as shark cartilage chondroitin sulfate C, and one or more of a hexosamine sulfate such as D-glucosamine sulfate, a flavone such as quercetin, an unrefined olive kernel extract that increases absorption of these compositions in various routes of administration, S-adenosylmethionine, a histamine-1 receptor antagonist, a histamine-3 receptor agonist, an antagonist of the actions of CRH, caffeine, and a polyamine.Type: GrantFiled: December 27, 2002Date of Patent: November 11, 2003Inventor: Theoharis C. Theoharides
-
Patent number: 6641806Abstract: Compositions with synergistic anti-inflammatory effects in inflammatory diseases resulting from activation and consequent degranulation of mast cells and followed by secretion of inflammatory biomolecules from the activated mast cells, composed of a heavily sulfated, non-bovine proteoglycan such as shark cartilage chondroitin sulfate C, and one or more of a hexosamine sulfate such as D-glucosamine sulfate, a flavone such as quercetin, an unrefined olive kernel extract that increases absorption of these compositions in various routes of administration, S-adenosylmethionine, a histamine-1 receptor antagonist, a histamine-3 receptor agonist, an antagonist of the actions of CRH, caffeine, and a polyamine.Type: GrantFiled: December 27, 2002Date of Patent: November 4, 2003Inventor: Theoharis C. Theoharides
-
Patent number: 6635625Abstract: Compositions with synergistic anti-inflammatory effects in inflammatory diseases resulting from activation and consequent degranulation of mast cells and followed by secretion of inflammatory biomolecules from the activated mast cells, composed of a heavily sulfated, non-bovine proteoglycan such as shark cartilage chondroitin sulfate C, and one or more of a hexosamine sulfate such as D-glucosamine sulfate, a flavone such as quercetin, an unrefined olive kernel extract that increases absorption of these compositions in various routes of administration, S-adenosylmethionine, a histamine-1 receptor antagonist, a histamine-3 receptor agonist, an antagonist of the actions of CRH, caffeine, and a polyamine.Type: GrantFiled: December 27, 2002Date of Patent: October 21, 2003Inventor: Theoharis C. Theoharides
-
Publication number: 20030190303Abstract: The present invention relates to pharmaceutical compositions and methods for treating allergic disorders characterized by a local immune response including inflammatory skin reactions, asthma, and arthritis.Type: ApplicationFiled: April 10, 1998Publication date: October 9, 2003Inventors: IAN KIMBER, MARIE CUMBERBATCH, REBECCA J. DEARMAN, ORLA M. CONNEELY, PAULINE WARD
-
Patent number: 6629835Abstract: A novel formulation is provided that serves to inhibit the inflammatory response in animals. The formulation comprises, as a first component an effective amount of a diterpene triepoxide lactone species and an effective amount of a second component selected from the group consisting of a diterpene lactone species and a triterpene species or derivatives thereof, and provides synergistic anti-inflammatory effects in response to physical or chemical injury or abnormal immune stimulation due to a biological agent or unknown etiology.Type: GrantFiled: August 1, 2001Date of Patent: October 7, 2003Assignee: MetaProteomics, LLCInventors: John G. Babish, Terrence Howell, Linda Pacioretty
-
Publication number: 20030175267Abstract: The use of compounds that block complement component or its active fragments C5a and/or C5b (such compounds collectively referred to as “C5 blockers”) to treat established joint inflammation (arthritis) is disclosed. Administration of such C5 blockers has been found to: 1) arrest and/or reduce inflammation in joints which are already inflamed, and 2) inhibit the spread of inflammation to unaffected joints.Type: ApplicationFiled: June 2, 1997Publication date: September 18, 2003Inventors: YI WANG, LOUIS MATIS
-
Patent number: 6610676Abstract: Compounds of the formula and use of the compounds as medicaments.Type: GrantFiled: April 2, 1999Date of Patent: August 26, 2003Assignee: Nicox S.A.Inventor: Piero Del Soldato
-
Patent number: 6608043Abstract: The present invention provides an agent for treatment of arthritic diseases such as rheumatoid arthritis that has for its active ingredient a complex of hyaluronic acid and zinc. This complex synergistically inhibits proliferation of synovial cells and suppresses matrix metalloproteinase MMP-9, which is produced by synovial cells, as compared with its constituents, hyaluronic acid and zinc, alone.Type: GrantFiled: September 7, 2001Date of Patent: August 19, 2003Assignees: Takata Seiyaku Co., Ltd., Richter Gedeon Vegyeszeti Gyar Rt.Inventors: Isao Serizawa, Keisei Maekawa, Janos Illes, Erzsebet Neszmeli
-
Patent number: 6607745Abstract: Methods are described for relieving discomforts associated with osteoarthritis or fibromyalgia. The methods comprise the step of delivering by oral ingestion a nutritional supplement consisting essentially of an effective amount of hyaluronic acid, or a salt or digest thereof, and a food acceptable carrier, wherein the effective amount of hyaluronic acid, or a salt or digest thereof, is from about 0.1 &mgr;g to about 400 &mgr;g/kg of body weight.Type: GrantFiled: May 18, 2001Date of Patent: August 19, 2003Inventor: Harry Leneau
-
Patent number: 6608044Abstract: The bioactivity of TNF is inhibited by administering heparin or a derivative thereof along with a soluble TNF receptor. The heparin or derivative thereof can be administered simultaneously with the soluble TNF receptor, either in separate compositions or in compositions containing both heparin or a derivative thereof and at least one soluble TNF receptor. The heparin or derivative may also be administered without the soluble TNF receptor and still effect some amount of inhibition of TNF bioactivity.Type: GrantFiled: November 20, 2000Date of Patent: August 19, 2003Assignee: Applied Research Systems ARS Holding N.V.Inventors: Dan Aderka, Talma Eshed (Englender)
-
Patent number: 6605639Abstract: It has been newly found out that ascochlorin, which is a publicly known fat-soluble antibiotic, and its homologues serve as a ligand of retinoid X receptor and react in vivo with the amino group of serum protein to form Schiff bases without showing any side effect of retinoid. Ascochlorin and its homologues are usable in treating and/or preventing a disease or condition which can be relieved by the retinoid X receptor ligand-dependent gene transcriptional regulation (for example, diseases caused by the expression of insulin resistance, hypertension, cerebrovascular diseases, rheumatoid arthritis, autoimmune disease, Ca metabolic disorder, complication of diabetes, arteriosclerosis, etc.). Moreover, they can inhibit denaturation and/or necrosis of pancreatic Langerhans islet &bgr;-cells and, therefore, are usable in making these cells to sustain the insulin productivity.Type: GrantFiled: June 14, 2001Date of Patent: August 12, 2003Assignee: Nuclear Receptor Research, Ltd.Inventors: Gakuzo Tamura, Kunio Ando, Junji Magae, Takafumi Uchida
-
Patent number: 6596687Abstract: The present invention relates to novel compounds that are useful for inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies. This invention also relates to pharmaceutical formulations comprising these compounds and methods of using them for inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies. The compounds and pharmaceutical compositions of this invention can be used as therapeutic or prophylactic agents. They are particularly well-suited for treatment of many inflammatory and autoimmune diseases.Type: GrantFiled: January 13, 2000Date of Patent: July 22, 2003Assignee: Biogen, Inc.Inventors: Ko-Chung Lin, Steven P. Adams, Alfredo C. Castro, Craig N. Zimmerman, Julio Hernan Cuervo, Wen-Cherng Lee, Charles E. Hammond, Mary Beth Carter, Ronald G. Almquist
-
Patent number: 6593359Abstract: The use of at least one &ggr;-RAR receptor-specific agonist ligand to prepare a pharmaceutical composition for increasing the rate of apoptosis in at least one cell population in which apoptosis may be induced by activating &ggr;-RAR receptors is disclosed. The composition is particularly useful for treating a disease or disorder related to an insufficient rate of apoptosis in at least one cell population in which apoptosis may be induced by activating &ggr;-RAR receptors. The use of at least one &ggr;-RAR receptor-specific agonist ligand as the apoptosis inducer in a cosmetic composition is also disclosed. Said composition may be used to prevent and/or control photo-ageing or chronological ageing of the skin.Type: GrantFiled: July 15, 1998Date of Patent: July 15, 2003Assignee: Centre International de Recherches Dermatologioues Galderma (C.I.R.D. Galderma)Inventors: Laszlo Fesus, Zsuzsa Szondy, Uwe Reichert
-
Patent number: 6592908Abstract: Nutritional or therapeutic compositions containing glutamic acid, cystine, glycine and a selenium precursor and methods for their utilization to increase glutathione synthesis and thereby enhance the immune system are described.Type: GrantFiled: September 23, 2002Date of Patent: July 15, 2003Inventor: Albert Crum
-
Patent number: 6555105Abstract: Modifications to RANTES can result in the modified polypeptide acting as a RANTES or MIP-1&agr; antagonist. Such antagonists can be used in therapy to reduce inflammation. They are also useful in studying the properties of RANTES or of MIP-1&agr;.Type: GrantFiled: August 17, 2000Date of Patent: April 29, 2003Assignee: Glaxo Group LimitedInventors: Amanda E. I. Proudfoot, Timothy N. C. Wells
-
Patent number: 6552033Abstract: The subject invention involves compounds having the structure: wherein each R1 is independently alkyl, aryl, or heterocycle; each R2-R7 is independently hydrogen or other substituent; B is nil and n is 0-3, or B is ethenyl and n is 0-1; and pharmaceutically acceptable forms thereof. The subject invention also involves pharmaceutical compositions containing such compounds, and methods for treating or preventing diseases or disorders using such compounds.Type: GrantFiled: February 13, 2002Date of Patent: April 22, 2003Assignee: The Procter & Gamble Co.Inventors: Song Liu, David Edward Portlock, Schwe Fang Pong
-
Patent number: 6548500Abstract: Conformationally constrained compounds which mimic the secondary structure of reverse-turn regions of biologically active peptides and proteins are disclosed. Such reverse-turn mimetics have utility in the treatment of cell adhesion-indicated diseases, such as multiple sclerosis, atherosclerosis, asthma and inflammatory bowel disease.Type: GrantFiled: December 19, 2000Date of Patent: April 15, 2003Assignee: Molecumetics Ltd.Inventors: Michael Kahn, Masakatsu Eguchi, Hwa-Ok Kim, Marcin Stasiak
-
Patent number: 6548540Abstract: Dithiocarbamate, particularly tetraethylthiuram disulfide, and thiocarbamate anions strongly inhibit the growth of cancer cells of a variety of cell types. Such inhibitory effect is enhanced by heavy metal ions such as copper ions, cytokines and ceruloplasmin. A method is presented for using tetraethylthiuram disulfide to reduce tumor growth, and to potentiate the effect of other anticancer agents.Type: GrantFiled: December 12, 2000Date of Patent: April 15, 2003Assignee: Charlotte-Mecklenburg Hospital AuthorityInventor: Thomas Preston Kennedy
-
Patent number: 6537590Abstract: A solution and the method of making the same for the treatment of osteoarthritis for treating symptoms of osteoarthritic conditions. The solution and the method of making the same for the treatment of osteoarthritis includes magnesium oxide; ethylenediaminetetraacetic acid; glycerin; and water, all of which are heated and added in a mixture which, after being cooled, is applied to the affected areas for treatment of the osteoarthritic condition.Type: GrantFiled: February 19, 2002Date of Patent: March 25, 2003Inventor: Troy J. Lee
-
Patent number: 6518274Abstract: The invention relates to the use of cycloventabenzofuran derivatives for the production of a medicament for the treatment of nuclear factor of &kgr;B-dependent diseases.Type: GrantFiled: April 18, 2001Date of Patent: February 11, 2003Assignee: Bayer AktiengesellschaftInventors: Matthias Gehling, Jörg Baumgarten, Axel Kretschmer, Horst-Peter Antonicek, Peter Proksch, Bambang Wahyu Nugroho, Frank Bohnenstengel
-
Patent number: 6518302Abstract: Compounds represented by general formula (I) wherein X represents OH or OSO3H; and R represents a substituent other than OH which allows, after leaving, the induction of unsaturated bonds into the 3- and 4-positions of 3,6-anhydrogalactose or its sulfated derivative, and/or a substituent showing a tissue-specific affinity.Type: GrantFiled: July 20, 2001Date of Patent: February 11, 2003Assignee: Takara Shuzo Co., Ltd.Inventors: Eiji Kobayashi, Tuo-Ping Li, Tatsuji Enoki, Takanari Tominaga, Hiroaki Sagawa, Ikunoshin Kato
-
Patent number: 6514540Abstract: A therapeutic composition for treating arthritis and other afflictions includes plantain and aloe vera constituents, which are approximately 0.01% to 0.1% and 0.1% to 1.0% by weight of the therapeutic composition, respectively. Other constituents, such as herbal tinctures, added for various purposes, may be approximately 5% to 10% by weight of the therapeutic composition. A joint compatible solution for injection directly into a human joint makes up approximately 99 to 99.9% by weight of the plantain constituent, and approximately 90 to 99.9% by weight of the aloe vera constituent, with the remaining approximately 0.1 to 1.0% by weight of the plantain constituent being extract from a plantain plant and the remaining approximately 0.1 to 10.0% by weight of the aloe vera constituent being extract from an aloe vera plant. The plantain extract acts as a medication, while the aloe vera extract acts as a vehicle to carry the plantain extract.Type: GrantFiled: September 6, 2001Date of Patent: February 4, 2003Inventor: Nancy Laning Sobczak
-
Patent number: 6509043Abstract: A composition comprising (a) soy protein, (b) a phytoestrogen compound, and (c) dietary fibers. The soy protein (a) is present in an amount of at least 45 weight percent of the total protein content of the composition, said total protein content providing at least 15% of the total energy content of the composition. The phytoestrogen compound (b) is preferably a naturally occurring isoflavone and is present in an amount of more than 0.10 weight percent of the soy protein, and the dietary fibers (c) are preferably soybean fibers and are present in an amount of more than 4 weight percent of the total weight of the nutritional composition on a dry basis. The composition is useful for treating pulmonary diseases.Type: GrantFiled: August 15, 2001Date of Patent: January 21, 2003Assignee: Nutri Pharma ASAInventor: Lars Henrik Høie
-
Patent number: 6506796Abstract: Methods of cosmetically or therapeutically treating diseases or disorders in cell populations whose pathology is linked to an inadequate rate of apoptosis by administering a therapeutically effective amount of 6-3-(1-adamantyl)-4-hydroxyphenyl)-2-naphthanoic acid.Type: GrantFiled: July 25, 2000Date of Patent: January 14, 2003Assignee: Centre International de Recherches Dermatologiques GaldermaInventors: Laszlo Fesus, Zsuzsa Szondy, Uwe Reichert
-
Patent number: 6495514Abstract: The invention relates to a method for reducing inflammation in a subject by administering to the subject an effective amount of the compound having the structure I or II: wherein, R1 is C1-C10 branched or straight chain alkyl, aryl, an amino acid, or a peptide; and R2 is hydrogen or lower C1-C5 branched or straight alkyl, or the salt or ester thereof, wherein the stereochemistry about the carbon-carbon double bond is trans. The invention further relates to a method of inducing an analgesic effect by administering to a subject an effective amount of the compound having the structure I or II. The invention further relates to a compound having the structure II, wherein, R1 is an N-acyl amino acid or peptide, or the salt or ester thereof.Type: GrantFiled: January 21, 1998Date of Patent: December 17, 2002Assignee: Mercer UniversityInventors: Sheldon W. May, Stanley H. Pollock
-
Patent number: 6495596Abstract: The present invention comprises a group of related lipid molecules, and methods for their use, that maybe used to treat inflammation and certain inflammation related diseases. The group of related lipid molecules are capable of inhibiting certain enzyme systems including phospholipase A2, and cyclooxygenase-2. The group of related lipid molecules of the invention may be characterized by specific structural characteristics, or by specific biological activity, including inhibition of the previously listed enzymes.Type: GrantFiled: June 7, 2001Date of Patent: December 17, 2002Assignee: Biozibe Laboratories, Inc.Inventor: Brian Keller
-
Patent number: 6488937Abstract: A method of treating a patient sensitive to an allergen includes a desensitizing rapid immunotherapy protocol of administering to the patient a series of gradually increasing doses of a composition comprising the allergen at intervals of about 15 minutes for a duration of less than about 120 minutes, and preferably less than about 90 minutes. A pretreatment protocol administers to the patient a therapeutically effective amount of at least one composition that is effective in reducing a sensitivity of the patient to an asthma associated allergenic reaction.Type: GrantFiled: August 23, 2000Date of Patent: December 3, 2002Inventor: William Smits
-
Patent number: 6485740Abstract: A methotrexate-containing transdermal preparation effective for rheumatoid arthritis comprises an organic amine. The organic amine may preferably be an alkonolamine such as monoethanolamine, diethanolamine, triethanolamine or diisopropanolamine, or an alkylamine such as ehtylamine, diethylamine or triethylamine. The transdermal preparation is, for example, a plaster, a cataplasm, an ointment, a cream or a lotion.Type: GrantFiled: March 14, 2000Date of Patent: November 26, 2002Assignee: Yutoku Pharmaceutical Ind., Co., Ltd.Inventors: Kenji Tominaga, Takaaki Hamada
-
Patent number: 6485752Abstract: A daily administration of a rose-hip concentrate and fish oil is used to treat and/or alleviate the symptoms associated with joint disease such as osteoarthritis, specifically joint pain and stiffness. By administering the combination on a daily basis, a significant reduction in pain and stiffness of the joints affected by joint disease is attained which allows individuals suffering from joint disease to substantially resume daily activities.Type: GrantFiled: October 23, 2000Date of Patent: November 26, 2002Inventor: Eydbjørg Rein
-
Patent number: 6476052Abstract: Substituted 1-oxo-2-(2,6-dioxopiperidin-3-yl)isoindolines are useful in treating inflammation, inflammatory disease, autoimmune disease, and oncogenic or cancerous conditions in a mammal. Typical embodiments are 1-oxo-2-(2,6-dioxopiperidin-3yl)4-aminoisoindoline and 1-oxo-2-(2,6-dioxo-3-methylpiperidin-3-yl)aminoisoindoline.Type: GrantFiled: August 7, 2000Date of Patent: November 5, 2002Assignee: Celgene CorporationInventors: George W. Muller, David I. Stirling, Roger Shen-Chu Chen
-
Patent number: 6476002Abstract: A method of treating a chronic inflammatory disease such as rheumatoid arthritis or psoriasis includes treating a patient with a toxin derived from Group B &bgr;-hemolytic Streptococcus bacteria. The purified GBS toxin, or CM101, may be administered. intravenously to the patient in repeated doses.Type: GrantFiled: October 28, 1999Date of Patent: November 5, 2002Assignee: Vanderbilt UniversityInventors: Carl G. Hellerqvist, Barbara D. Wamil
-
Patent number: 6464985Abstract: An OspC Dra fragment fusion peptide isolated from Borrelia burgdorferi is described herein for the prevention, treatment and early diagnosis of Lyme disease in humans and other animals. This invention also relates to a screening method detecting anti-Osp borreliacidal antibody activity, and antibodies reacting with a protein fragment encoded by a DraI-SmaI DNA fragment of OspC.Type: GrantFiled: August 30, 2000Date of Patent: October 15, 2002Assignee: Gundersen Lutheran Medical Foundation, Inc.Inventors: Steven M. Callister, Steven D. Lovrich, Ronald F. Schell, Dean A. Jobe
-
Patent number: 6455497Abstract: The invention provides methods and materials related to the treatment of inflammatory diseases such as rheumatoid arthritis. Specifically, the invention provides methods and materials for treating inflammation by reducing production of an inflammatory cytokine such as IFN-&ggr;, IL-, and TNF-&agr;. The invention also provides methods and materials for identifying reagents that can be used to treat inflammatory diseases. Specifically, the invention provides non-human animals containing human synovial tissue as well as methods for using such non-human animals to determine the influence of various test reagents on the inflamed state of human synovial tissue.Type: GrantFiled: November 30, 2000Date of Patent: September 24, 2002Assignee: Mayo Foundation for Medical Education and ResearchInventors: Jorg J. Goronzy, Cornelia M. Weyand
-
Patent number: 6444709Abstract: The invention relates to novel heteroethynylenic compounds having the general formula (I): as well as to the use of these compounds in pharmaceutical compositions intended for use in human or veterinary medicine (dermatological, rheumatic, respiratory, cardiovascular and ophthalmological complaints in particular), or alternatively in cosmetic compositions.Type: GrantFiled: February 7, 2000Date of Patent: September 3, 2002Assignee: Galderma Research & Development S.N.C.Inventors: Philippe Diaz, Jean-Michel Bernardon